VAMSI LABS LTD

Overview

VAMSI LABS LTD is an active pharmaceutical ingredient (API) supplier with 7 active FDA Type II Drug Master Files, covering ALBUTEROL SULFATE USP; FLUTICASONE PROPIONATE USP; FORMOTEROL FUMARATE DIHYDRATE USP; HALOPERIDOL USP; LOPERAMIDE HYDROCHLORIDE USP; TIOTROPIUM BROMIDE MONOHYDRATE.

API / Drug Master Files

VAMSI LABS LTD holds 7 active (16 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• TRIAMCINOLONE ACETONIDE USPActive2026-03-11
• FLUTICASONE PROPIONATE USPActive2025-11-25
• ALBUTEROL SULFATE USPActive2025-11-22
• FORMOTEROL FUMARATE DIHYDRATE USPActive2025-11-01
• LOPERAMIDE HYDROCHLORIDE USPActive2025-09-16
• TIOTROPIUM BROMIDE MONOHYDRATEActive2020-04-15
• HALOPERIDOL USPActive2019-11-14
• SALBUTAMOL SULFATE- EPInactive2024-09-30
• CYPROHEPTADINE HYDROCHLORIDE- EPInactive2024-09-30
• FENOTEROL HYDROBROMIDE-EPInactive2024-09-26
• FORMOTEROL FUMARATE DIHYDRATE EPInactive2024-08-31
• IPRATROPIUM BROMIDE-EPInactive2024-08-28
• FLUTICASONE FUROATE EPInactive2024-08-26
• SALMETEROL XINAFOATE EPInactive2024-08-13
• FLUTICASONE PROPIONATE EPInactive2024-08-13

Showing 15 of 16 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to VAMSI LABS LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.